Overview

Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
Following a radical prostatectomy and lymph node sampling, eligible patients will undergo post-operative radiation therapy, concurrent weekly docetaxel chemotherapy , and hormonal therapy (Casodex daily and Zoladex every 3 months for 2 times or Lupron 22.5 mg im every 3 months for 2 times).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Kansas Medical Center
Treatments:
Bicalutamide
Docetaxel
Goserelin
Leuprolide